Matthew J Heussner1,2, Joseph K Folger1, Christina Dias3, Noura Massri1, Albert Dahdah4, Paola D Vermeer5, Geoffroy Laumet1,3. 1. From the Department of Physiology and. 2. College of Osteopathic Medicine, Michigan State University, East Lansing, Michigan. 3. Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, Texas. 4. Department of Microbiology & Molecular Genetics, Michigan State University, East Lansing, Michigan. 5. Cancer Biology and Immunotherapies Group, Sanford Research, Sioux Falls, South Dakota.
Abstract
BACKGROUND: Pain is one of the first presenting symptoms in patients with head and neck cancer, who often develop chronic and debilitating pain as the disease progresses. Pain is also an important prognostic marker for survival. Unfortunately, patients rarely receive effective pain treatment due to our limited knowledge of the mechanisms underlying head and neck cancer pain (HNCP). Pain is often associated with neuroinflammation and particularly interleukin (IL)-1 signaling. The purpose of this study is to develop a novel syngeneic model of HNCP in immunocompetent mice to examine the contribution of IL-1 signaling. METHODS: Male C57BL/6 mice were injected with a murine model of human papillomavirus (HPV+)-induced oropharyngeal squamous cell carcinoma in their right hindlimb to induce tumor growth. Pain sensitivity was measured via von Frey filaments. Spontaneous pain was assessed via the facial grimace scale. IL-1β was measured by quantifying gene expression via quantitative polymerase chain reaction (qPCR) and enzyme-linked immunosorbent assay (ELISA). RESULTS: Pain hypersensitivity and spontaneous pain develop quickly after the implantation of tumor cells, a time when tumor volume is still insignificant. Spinal and circulating IL-1β levels are significantly elevated in tumor-bearing mice. Blocking IL-1 signaling either by intrathecal administration of interleukin-1 receptor antagonist (IL-1ra) or by genetic deletion (interleukin-1 receptor knockout [Il1r1-/-]) does not alleviate HNCP. CONCLUSIONS: We established the first syngeneic model of HNCP in immunocompetent mice. Unlike inflammatory or nerve-injured pain, HNCP is independent of IL-1 signaling. These findings challenge the common belief that pain results from tissue compression or IL-1 signaling in patients with head and neck cancer.
BACKGROUND: Pain is one of the first presenting symptoms in patients with head and neck cancer, who often develop chronic and debilitating pain as the disease progresses. Pain is also an important prognostic marker for survival. Unfortunately, patients rarely receive effective pain treatment due to our limited knowledge of the mechanisms underlying head and neck cancer pain (HNCP). Pain is often associated with neuroinflammation and particularly interleukin (IL)-1 signaling. The purpose of this study is to develop a novel syngeneic model of HNCP in immunocompetent mice to examine the contribution of IL-1 signaling. METHODS: Male C57BL/6 mice were injected with a murine model of human papillomavirus (HPV+)-induced oropharyngeal squamous cell carcinoma in their right hindlimb to induce tumor growth. Pain sensitivity was measured via von Frey filaments. Spontaneous pain was assessed via the facial grimace scale. IL-1β was measured by quantifying gene expression via quantitative polymerase chain reaction (qPCR) and enzyme-linked immunosorbent assay (ELISA). RESULTS: Pain hypersensitivity and spontaneous pain develop quickly after the implantation of tumor cells, a time when tumor volume is still insignificant. Spinal and circulating IL-1β levels are significantly elevated in tumor-bearing mice. Blocking IL-1 signaling either by intrathecal administration of interleukin-1 receptor antagonist (IL-1ra) or by genetic deletion (interleukin-1 receptor knockout [Il1r1-/-]) does not alleviate HNCP. CONCLUSIONS: We established the first syngeneic model of HNCP in immunocompetent mice. Unlike inflammatory or nerve-injured pain, HNCP is independent of IL-1 signaling. These findings challenge the common belief that pain results from tissue compression or IL-1 signaling in patients with head and neck cancer.
Authors: Cielito C Reyes-Gibby; Karen O Anderson; Kelly W Merriman; Knox H Todd; Sanjay S Shete; Ehab Y Hanna Journal: J Pain Date: 2014-07-17 Impact factor: 5.820
Authors: Elisabeth G Vichaya; Daniel W Vermeer; Diana L Christian; Jessica M Molkentine; Kathy A Mason; John H Lee; Robert Dantzer Journal: Psychoneuroendocrinology Date: 2017-02-11 Impact factor: 4.905
Authors: Elizabeth Salvo; Wendy M Campana; Nicole N Scheff; Tu Huu Nguyen; Se-Hee Jeong; Ian Wall; Angie K Wu; Susanna Zhang; Hyesung Kim; Aditi Bhattacharya; Malvin N Janal; Cheng Liu; Donna G Albertson; Brian L Schmidt; John C Dolan; Robert E Schmidt; M Danilo Boada; Yi Ye Journal: Pain Date: 2020-11 Impact factor: 6.961
Authors: Marianna Madeo; Paul L Colbert; Daniel W Vermeer; Christopher T Lucido; Jacob T Cain; Elisabeth G Vichaya; Aaron J Grossberg; DesiRae Muirhead; Alex P Rickel; Zhongkui Hong; Jing Zhao; Jill M Weimer; William C Spanos; John H Lee; Robert Dantzer; Paola D Vermeer Journal: Nat Commun Date: 2018-10-16 Impact factor: 14.919
Authors: Coleen Doan; Bradley E Aouizerat; Yi Ye; Dongmin Dang; Kesava Asam; Aditi Bhattacharya; Timothy Howard; Yogin K Patel; Dan T Viet; Johnny D Figueroa; Jiang F Zhong; Carissa M Thomas; Anthony B Morlandt; Gary Yu; Nicholas F Callahan; Clint T Allen; Anupama Grandhi; Alan S Herford; Paul C Walker; Khanh Nguyen; Stephanie C Kidd; Steve C Lee; Jared C Inman; Jason M Slater; Chi T Viet Journal: Adv Biol (Weinh) Date: 2022-08-04